Drug Profile
PRO 045
Alternative Names: BMN-045; PRO045Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Prosensa
- Developer BioMarin Nederland
- Class Antisense oligonucleotides
- Mechanism of Action Antisense RNA modulators; Dystrophin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 31 May 2016 Discontinued - Phase-II for Duchenne muscular dystrophy (In adolescents, In children) in Netherlands, United Kingdom, Italy, France, Belgium (SC)
- 28 Apr 2015 Prosensa Therapeutics is now called BioMarin Nederland
- 30 Mar 2015 Phase-II clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Belgium, France, Italy, United Kingdom and Netherlands (SC)